|
Orthologous residues
|
|
IGF1R (human): Y1165‑p, IGF1R (mouse): Y1167‑p, IGF1R (rat): Y1166‑p, IGF1R (pig): Y1165‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site, phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout]
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
IGF1R (human)
|
pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
IGF-1
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Comments:
Signaling through Shc and IRS-1 pathways, IGF-1-stimulated cell growth in culture and tumor formation in nude mice.
|